Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)

v3.6.0.2
Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Expenses        
Research and development $ 1,120,910 $ 789,187 $ 1,853,639 $ 1,393,032
General and administrative 571,286 890,672 1,887,925 1,364,697
Operating expenses 1,692,196 1,679,859 3,741,564 2,757,729
Other loss (income)        
Change in fair value of stock option and derivative liabilities (361,668) 680,188 (135,980) 1,219,634
Change in fair value of derivative liability due to change in warrant terms 242,400 263,965
Foreign exchange (8,495) 44,253 6,829 26,780
Interest income (60) (10) (101) (30)
Other (income) loss (370,223) 966,831 (129,252) 1,510,349
Net and comprehensive loss for the period 1,321,973 2,646,690 3,612,312 4,268,078
Computation of basic loss per share        
Net and comprehensive loss for the period (1,321,973) (2,646,690) (3,612,312) (4,268,078)
Series B Preferred stock dividend 159,756 467,054
Net and comprehensive loss available to common stockholders $ (1,481,729) $ (2,646,690) $ (4,079,366) $ (4,268,078)
Basic and fully diluted loss per share $ 0.13 $ 0.24 $ 0.36 $ 0.40
Basic weighted average number of shares 11,424,485 10,994,879 11,363,237 10,808,660